Julie E. Stein

3.2k total citations · 1 hit paper
24 papers, 1.0k citations indexed

About

Julie E. Stein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Julie E. Stein has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Immunology. Recurrent topics in Julie E. Stein's work include Cancer Immunotherapy and Biomarkers (11 papers), Cancer Genomics and Diagnostics (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Julie E. Stein is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Cancer Genomics and Diagnostics (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Julie E. Stein collaborates with scholars based in United States, Germany and Netherlands. Julie E. Stein's co-authors include Janis M. Taube, Drew M. Pardoll, Robert A. Anders, Hao Wang, Ludmila Danilova, Jeffrey A. Sosman, Douglas B. Johnson, Kurt A. Schalper, Clifford Hoyt and David L. Rimm and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Julie E. Stein

22 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

2019 405 citations Julie E. Stein, Jeffrey A. Sosman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie E. Stein United States	12	658	281	275	231	211	24	1.0k
Roberta Depenni Italy	18	679 1.0×	306 1.1×	125 0.5×	352 1.5×	270 1.3×	58	1.1k
Joan Somja Belgium	21	542 0.8×	199 0.7×	397 1.4×	297 1.3×	452 2.1×	56	1.5k
Philipp Lohneis Germany	19	643 1.0×	169 0.6×	300 1.1×	182 0.8×	265 1.3×	57	1.1k
Antonella De Stefani Italy	18	436 0.7×	223 0.8×	247 0.9×	250 1.1×	315 1.5×	37	1.2k
Edmund Poon United Kingdom	10	1.3k 2.0×	457 1.6×	732 2.7×	178 0.8×	199 0.9×	18	1.7k
Ritesh Rathore United States	15	837 1.3×	242 0.9×	239 0.9×	125 0.5×	217 1.0×	44	1.0k
Thomas R. Nirschl United States	15	1.0k 1.5×	443 1.6×	677 2.5×	187 0.8×	222 1.1×	33	1.4k
Youjin Lee South Korea	8	912 1.4×	361 1.3×	564 2.1×	132 0.6×	189 0.9×	10	1.3k
Rohit Sharma United States	9	990 1.5×	506 1.8×	475 1.7×	320 1.4×	115 0.5×	24	1.5k

Countries citing papers authored by Julie E. Stein

Since Specialization

Citations

This map shows the geographic impact of Julie E. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie E. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie E. Stein more than expected).

Fields of papers citing papers by Julie E. Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie E. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie E. Stein. The network helps show where Julie E. Stein may publish in the future.

Co-authorship network of co-authors of Julie E. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Julie E. Stein. A scholar is included among the top collaborators of Julie E. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie E. Stein. Julie E. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stein, Julie E., et al.. (2022). Abstract 463: Highly accurate machine learning assessment of immune-related pathologic response criteria (irPRC) scoring in patients with non-small cell lung carcinoma (NSCLC) treated with neoadjuvant anti-PD-1-based therapies. Cancer Research. 82(12_Supplement). 463–463.

Schenk, Kara M., Julie E. Stein, Sunandana Chandra, et al.. (2022). Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.. Journal of Clinical Oncology. 40(16_suppl). 9507–9507. 14 indexed citations

Kaunitz, Genevieve J., Julie E. Stein, Travis J. Hollmann, et al.. (2022). Immune cell subsets in interface cutaneous immune‐related adverse events associated with anti‐PD‐1 therapy resemble acute graft versus host disease more than lichen planus. Journal of Cutaneous Pathology. 49(8). 701–708. 4 indexed citations

Giraldo, Nicolás A., Sneha Berry, Étienne Becht, et al.. (2021). Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. Cancer Immunology Research. 9(11). 1262–1269. 6 indexed citations

Ferris, Robert L., William C. Spanos, Rom S. Leidner, et al.. (2021). Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. Journal for ImmunoTherapy of Cancer. 9(6). e002568–e002568. 126 indexed citations

Gorin, Michael A., Hiten D. Patel, Steven P. Rowe, et al.. (2021). Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. European Urology Oncology. 5(1). 113–117. 40 indexed citations

Reuss, Joshua E., Boris Sepesi, Christian Rolfo, et al.. (2020). Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.. Journal of Clinical Oncology. 38(15_suppl). TPS9078–TPS9078. 1 indexed citations

Thummalapalli, Rohit, Thatcher Heumann, Julie E. Stein, et al.. (2020). Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. Case Reports in Oncology. 13(2). 508–514. 14 indexed citations

Succaria, Farah, Pia Kvistborg, Julie E. Stein, et al.. (2020). Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Cancer Immunology Immunotherapy. 70(5). 1227–1237. 34 indexed citations

10.

Berry, Sneha, Nicolás A. Giraldo, Benjamin Green, et al.. (2020). Abstract 6584: The ‘AstroPath' platform for spatially resolved, single cell analysis of the tumor microenvironment (TME) using multispectral immunofluorescence (mIF). Cancer Research. 80(16_Supplement). 6584–6584. 3 indexed citations

11.

Stein, Julie E., Evan J. Lipson, Tricia R. Cottrell, et al.. (2019). Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research. 26(3). 545–551. 92 indexed citations

12.

Stein, Julie E., Abhishek Soni, Ludmila Danilova, et al.. (2019). Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Annals of Oncology. 30(4). 589–596. 35 indexed citations

13.

Schollenberger, Megan D., Julie E. Stein, Janis M. Taube, & Evan J. Lipson. (2019). Poliosis Circumscripta: A Mark of Melanoma. The American Journal of Medicine. 132(12). 1417–1418. 2 indexed citations

14.

Stein, Julie E., et al.. (2019). A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (laBCC) or metastatic basal cell carcinoma (mBCC).. Journal of Clinical Oncology. 37(15_suppl). TPS9595–TPS9595. 6 indexed citations

15.

Sommerfeld, Sven D., Christopher Cherry, Liam Chung, et al.. (2019). Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis. Science Immunology. 4(40). 122 indexed citations

16.

Stein, Julie E., et al.. (2018). Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis. BMJ Case Reports. 2018. bcr–2017. 4 indexed citations

17.

Topalian, Suzanne L., Shailender Bhatia, Ragini R. Kudchadkar, et al.. (2018). Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.. Journal of Clinical Oncology. 36(15_suppl). 9505–9505. 29 indexed citations

18.

Shah, Chirag, et al.. (2012). Survival After Chemoradiation in Resected Pancreatic Cancer: The Impact of Adjuvant Gemcitabine. International Journal of Radiation Oncology*Biology*Physics. 83(3). e331–e335. 6 indexed citations

19.

Stein, Julie E., et al.. (2006). [Adenocarcinoma of the esophagogastric junction (AEG-tumor). Review of the literature].. PubMed. 26(2). 194–9. 1 indexed citations

20.

Kern, Wolfgang, Nicola Lang, Hans‐Joachim Stemmler, et al.. (2001). Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Annals of Oncology. 12(5). 599–603. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact